insitro
Insitro is a biotechnology company that leverages machine learning and large-scale data analysis to expedite drug discovery and development, focusing on metabolism, oncology, and neuroscience.
Services
Insitro utilizes machine learning and data at scale to accelerate drug discovery and development. Their ML-driven platform integrates in vitro cellular data with human clinical data to redefine disease and develop new medicines. The company also employs machine learning-enabled analysis of histopathology images to derive insights into the biology of the tumor microenvironment. Additionally, they generate multi-modal phenotypic cellular data in automated laboratories and aggregate clinical data from human cohorts to fuel their machine learning and generative AI processes.
Therapeutic Programs
Insitro is building a pipeline of therapeutic programs in the fields of metabolism, oncology, and neuroscience. The company's pipeline includes both wholly-owned and partnered therapeutic programs. They focus on diseases with significant unmet needs, such as Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, under a partnership with Bristol Myers Squibb, and research on metabolic-associated steatotic liver disease (MASLD) and obesity.
Partnerships
Insitro has established a partnership with Bristol Myers Squibb to discover and develop treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. This collaboration aims to leverage Insitro's machine learning capabilities to identify novel therapeutic targets and develop new treatments for these neurodegenerative conditions.
Advanced Research Areas
Insitro focuses on advanced research addressing various significant medical conditions. They are specifically engaged in research on metabolic pathologies, with a focus on metabolic-associated steatotic liver disease (MASLD) and obesity. Additionally, they leverage human genetics to identify causal intervention points in disease and turn them into effective therapeutic interventions. Their research spans across metabolism, oncology, and neuroscience, aiming to decode the complexities of biology and unlock transformative new medicines.
Financing and Location
Insitro has raised $400 million in Series C financing to advance its machine learning drug discovery initiatives. The company is located at 279 East Grand Avenue, South San Francisco, California 94080. This funding aims to support their ongoing research and development efforts, as well as to enhance their ML-driven platforms and therapeutic program pipelines.